Mallis P, Chatzistamatiou T, Dimou Z, Sarri EF, Georgiou E, Salagianni M, Triantafyllia V, Andreakos E, Stavropoulos-Giokas C, Michalopoulos E. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results. World J Biol Chem 2022; 13(2): 47-65 [PMID: 35432769 DOI: 10.4331/wjbc.v13.i2.47]
Corresponding Author of This Article
Panagiotis Mallis, MSc, PhD, Associate Research Scientist, Teaching Assistant, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, No. 4 Soranou Ephessiou Street, Athens 11527, Greece. pmallis@bioacademy.gr
Research Domain of This Article
Cell Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Panagiotis Mallis, Theofanis Chatzistamatiou, Zetta Dimou, Eirini-Faidra Sarri, Eleni Georgiou, Catherine Stavropoulos-Giokas, Efstathios Michalopoulos, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, Athens 11527, Greece
Maria Salagianni, Vasiliki Triantafyllia, Evangelos Andreakos, Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, Athens 11527, Greece
Author contributions: Mallis P designed the study, performed the experimental procedures and statistical analysis, and prepared the whole manuscript; Sarri EF, Dimou Z, and Georgiou E contributed to performing the experimental procedures; Salagianni M and Triantafyllia V contributed to performing the experimental procedures and data analysis; Michalopoulos E, Chatzistamatiou T, and Andreakos E made critical revisions related to the content of the manuscript; Stavropoulos-Giokas C and Michalopoulos E performed the final approval of the manuscript.
Institutional review board statement: The overall study has received approval from the Institution’s ethical board (Reference No. 1754, January 21, 2021).
Informed consent statement: The patient's legal guardian provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare no conflict of interest for the current study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Panagiotis Mallis, MSc, PhD, Associate Research Scientist, Teaching Assistant, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, No. 4 Soranou Ephessiou Street, Athens 11527, Greece. pmallis@bioacademy.gr
Received: November 6, 2021 Peer-review started: November 6, 2021 First decision: December 27, 2021 Revised: December 28, 2021 Accepted: March 6, 2022 Article in press: March 6, 2022 Published online: March 27, 2022 Processing time: 136 Days and 17.3 Hours
Core Tip
Core Tip: Coronavirus disease 2019 (COVID-19) is responsible for the acute respiratory distress syndrome occurrence, a disorder that might prove life-threatening for a great number of hospitalized patients. As an alternative to the already evaluated therapeutic protocols, mesenchymal stromal cells (MSCs) can be evaluated as a potential stem cell therapy. MSCs exert key immunoregulatory properties, either through direct or indirect contact. In the current study, stimulated Wharton’s Jelly and bone marrow-MSCs produced high levels of anti-inflammatory cytokines and growth factors and also efficiently performed the M2 phenotype switch of macrophages. Considering this data, MSCs could be considered as a valuable stem cell therapy for better COVID-19 management.
